北京世辉律师事务所 关于山东科源制药股份有限公司 2025 年第三次临时股东大会的 法律意见书 致：山东科源制药股份有限公司 北京世辉律师事务所（以下简称"本所"）为具有从事法律业务资格的律师事 务所。本所接受山东科源制药股份有限公司（以下简称"公司"）的委托，指派本 所律师根据《中华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证 券法》"）《上市公司股东会规则》等有关法律、法规、规范性文件（以下统称 "法律法规"）及《山东科源制药股份有限公司章程》（以下简称"《公司章程》"） 的规定，就公司 2025 年第三次临时股东大会（以下简称"本次股东大会"）相关 事宜出具本法律意见书。 本所及本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见书所认定的事实真实、准确、 完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大 遗漏，并承担相应法律责任。 为出具本法律意见书，本所律师查阅了公司提 ...

Core Viewpoint - On September 28, Linuo Group celebrated its 31st anniversary, coinciding with the completion and commissioning of its subsidiary Koyuan Pharmaceutical's intelligent factory for injectable products [1] Group 1: Project Overview - The intelligent factory, characterized by "AI + computing power," was fully invested and constructed by Linuo Pharmaceutical, covering a total area of approximately 46,000 square meters [1] - The facility includes quality inspection and R&D buildings, high-end injectable production workshops, and a comprehensive intelligent storage warehouse [1] - The production and quality management systems are established according to national GMP, US FDA, and EU GMP standards, making it a high-end intelligent manufacturing plant for injectables [1] Group 2: Strategic Importance - The project is recognized as a key project for green, low-carbon, and high-quality development in Shandong Province, as well as a significant initiative for enterprise technological transformation and major industrial breakthroughs in the province [1] Group 3: Company Positioning - Koyuan Pharmaceutical is a leading player in the domestic chemical raw material drug sector, with its subsidiary Linuo Pharmaceutical focusing on formulations [1] - The company has built strong capabilities and competitive advantages in areas such as hypoglycemic agents, cardiovascular drugs, and central nervous system medications [1] - The completion of this project marks a significant transition for Koyuan Pharmaceutical and Linuo Pharmaceutical from oral solid formulations to the high-barrier injectable sector, accelerating the formation of a new industrial ecosystem with multiple dosage forms coexisting and thriving together [1]

Core Insights - The establishment of two AI-driven smart factories by Linuo Group marks a significant advancement in the AI transformation of its health industry, enhancing its competitive edge in the pharmaceutical sector [2][4][6] Group 1: Company Overview - Linuo Group, founded in 1994 and headquartered in Jinan, Shandong, is a leading enterprise in China's manufacturing sector, recognized as one of the top 500 manufacturing companies and one of the top 100 private enterprises in Shandong [2] - The company operates in various sectors, including health, new energy, and new materials, with a focus on integrating advanced technologies into its production processes [2] Group 2: Project Details - The "AI + Computing Power" smart factory for Linuo Pharmaceutical's injection project has been completed with a total investment of 900 million yuan and a construction area of approximately 46,000 square meters [3] - This smart factory adheres to national and international quality standards, including GMP, FDA, and EU GMP, and integrates advanced production and quality management systems [3][5] Group 3: Technological Integration - The smart factory incorporates cutting-edge pharmaceutical equipment and digital innovation technologies, establishing a comprehensive intelligent manufacturing system that enhances production efficiency and quality [4][5] - The factory's design follows the CMMM Level 4 intelligent manufacturing maturity standard, integrating AI technologies for prescription analysis and automated production processes [6][7] Group 4: Environmental and Operational Efficiency - The factory has implemented a digital traceability system covering the entire lifecycle of traditional Chinese medicine, achieving 100% automatic collection of 35 key traceability indicators [7] - Innovative energy recycling systems and drone delivery services have been introduced, significantly reducing carbon emissions and improving delivery efficiency for urgent medical needs [7][8] Group 5: Future Prospects - The smart factory is expected to begin trial production by October 2025, with an anticipated annual output value of 20 million yuan, contributing to the modernization and internationalization of traditional Chinese medicine [8]

Core Insights - The completion of the AI-powered intelligent factory for injectable drugs by Koyuan Pharmaceutical's subsidiary, Linuo Pharmaceutical, marks a significant breakthrough in smart manufacturing within the injectable drug sector [1][3][4] - The project encompasses a total construction area of approximately 46,000 square meters, featuring quality inspection and R&D buildings, high-end injectable drug production workshops, and a comprehensive intelligent warehouse [3][4] Group 1: Project Overview - The factory's production and quality management systems are established according to national GMP, US FDA, and EU GMP standards, integrating smart, lean, green, and safe production [3][11] - The project is recognized as a key initiative for green, low-carbon, and high-quality development in Shandong Province, as well as a significant project for enterprise technological transformation and industrial upgrades [3][4] Group 2: Technological Advancements - The factory employs advanced technologies such as 4K ultra-high-definition monitoring, 5G high-speed transmission, and AI intelligent analysis to create a smart park platform that optimizes energy consumption and ensures ecological compliance [5][10] - The production system integrates cutting-edge pharmaceutical equipment and digital innovation technologies, featuring two production lines for freeze-dried powder injections and BFS (Blow-Fill-Seal) technology [7][10] Group 3: Quality Control and Logistics - The smart laboratory establishes a new paradigm for digital transformation in pharmaceutical quality control, utilizing AI central control systems and intelligent robotic clusters for fully automated operations [8] - The intelligent warehouse employs a four-way car storage system and WMS (Warehouse Management System) to ensure real-time synchronization of inventory data, enhancing the efficiency of the pharmaceutical supply chain [9] Group 4: Strategic Positioning - The factory's production and quality systems are designed to meet international standards, enhancing product quality recognition and market access, particularly for high-end markets in Europe and the US [11] - The establishment of this intelligent factory is a key strategic move for Koyuan Pharmaceutical and Linuo Pharmaceutical, aimed at expanding their high-end formulation product matrix and enhancing market competitiveness [11]

证券代码：301281 证券简称：科源制药 公告编号：2025-071 山东科源制药股份有限公司 关于股东减持计划期限届满暨减持结果公告 公司持股5%以上股东问泽鸿先生及其一致行动人保证向本公司提供的信息 内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于 2025 年 5 月 26 日披露 了《关于持股 5%以上股东股份减持计划的预披露公告》（公告编号：2025-040）， 股东问泽鸿先生计划在上述公告披露之日起十五个交易日后的三个月内以集中 竞价方式及大宗交易方式减持公司股份不超过 3,248,700 股（不超过公司总股本 的 3.00%）。其中以集中竞价交易方式减持公司股份不超过 1,082,900 股（占公 司总股本的 1.00%），以大宗交易方式减持公司股份不超过 2,165,800 股（占公 司总股本的 2.00%）。 公司近日收到股东问泽鸿先生出具的《关于股份减持计划期限届满的告知 函》，现将相关情况公告如下： 一、股东减持计划实施情况 注：股 ...

Core Insights - The "2025 China Listed Companies Excellence Demonstration Case Selection" results were announced, with Koyuan Pharmaceutical (301281.SZ) Secretary Li Chunhua awarded the "Outstanding Secretary" title [1] - The selection aims to promote high-quality development in China's capital market and advocates for value and long-term investment [1] Company Overview - Koyuan Pharmaceutical is a leading company in the domestic chemical raw materials drug sector, focusing on chronic disease areas such as diabetes, anesthesia, cardiovascular, and central nervous system disorders [1] - The company specializes in the R&D, production, and sales of chemical raw materials and formulations, with all products certified by national GMP and core products holding EU CEP certification [1] Product Development and Strategy - The company is enhancing its product development capabilities and expanding its product range, currently offering various categories of drugs including diabetes, anesthesia, cardiovascular, and psychiatric medications [1] - Key products include mature raw materials such as Glimepiride, Metformin Hydrochloride, Ropivacaine Hydrochloride, and Isosorbide Mononitrate, contributing to stable revenue and profit [1] Mergers and Acquisitions - Koyuan Pharmaceutical is actively pursuing an integrated development strategy of "raw materials + formulations" through the acquisition of Lino Pharmaceutical, which adds new growth potential [2] - The company has successfully passed anti-monopoly review for the acquisition of 99.42% equity in Shandong Hongjitang Pharmaceutical Group [2] Management Team - The management team consists of high-quality experts with multidisciplinary backgrounds and extensive experience in the chemical raw materials drug industry [2] - The team emphasizes sustainable long-term development and core competitiveness, implementing effective management systems across R&D, procurement, production, marketing, and human resources [2] Future Outlook - Koyuan Pharmaceutical will continue to adhere to its values of "long-termism, productism, and altruism," focusing on chronic disease areas and diversifying into other niche markets [2] - The company aims to enhance R&D capabilities and expand its core competitiveness through integrated raw material and formulation strategies [2]

证券代码：301281 证券简称：科源制药 公告编号：2025-067 山东科源制药股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日召开 第四届董事会第十二次会议，审议通过了《关于提请召开 2025 年第三次临时股 东大会的议案》，公司董事会决定于 2025 年 9 月 29 日 15:00 以现场投票与网络 投票相结合的方式召开公司 2025 年第三次临时股东大会（以下简称 "本次股东 大会"），现将会议的有关情况通知如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2025 年第三次临时股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开经过董事会审议通过， 会议的召集、召开符合有关法律、行政法规、部门规章、其他规范性文件及《山 东科源制药股份有限公司章程》的有关规定。 4、会议召开的日期与时间 （1）现场会议召开时间：2025 年 9 月 29 日（星期一）15:00 （ ...

证券代码：301281 证券简称：科源制药 公告编号：2025-070 山东科源制药股份有限公司 关于召开2025年第三次临时股东大会的通知的更正公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）已于 2025 年 9 月 13 日披露了《关于召 开 2025 年第三次临时股东大会的通知》（公告编号 2025-067）。经审查，原公告中投票代码 和投票简称有误，现对该公告中的内容予以更正，敬请投资者关注。具体内容如下： 更正前： …… 附件一： 参加网络投票的具体操作流程 一、网络投票的程序 …… 更正后： 参加网络投票的具体操作流程 一、网络投票的程序 …… 1、投票代码：301281 2、投票简称：科源制药 1、投票代码：351281 2、投票简称：科源投票 除上述更正内容外，公告中的其他内容不变。更正后的公告详见公司同日披露于 巨潮资讯网（www.cninfo.com.cn）的《关于召开2025年第三次临时股东大会的通知 （更正后）》。公司对上述失误给投资者带来的不便深表歉意，敬请广大投资者谅解。 特此公告 ...

第一章 总则 第一条 为进一步加强山东科源制药股份有限公司（以下简称"本公司"或 者"公司"）关联交易管理，明确管理职责和分工，维护公司股东和债权人的合 法利益，特别是中小投资者的合法权益，保证公司与关联人之间订立的关联交易 合同符合公平、公开、公允的原则，根据《中华人民共和国公司法》、中华人民 共和国财政部颁布的《企业会计准则》以及《山东科源制药股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，特制订本制度。 山东科源制药股份有限公司 关联交易管理制度 2025 年 9 月 山东科源制药股份有限公司 关联交易管理制度 山东科源制药股份有限公司 关联交易管理制度 （三）由本制度第五条所列公司的关联自然人直接或者间接控制的、或者担 任董事（独立董事除外）、高级管理人员的，除公司及其控股子公司以外的法人 或者其他组织； （四）持有公司 5%以上股份的法人或者一致行动人； （五）中国证监会、深圳证券交易所或者公司根据实质重于形式的原则认定 的其他与公司有特殊关系，可能造成公司对其利益倾斜的法人或者其他组织。 公司与前款第（二）项所列法人受同一国有资产管理机构控制而形成前款第 （二）项所述情形的，不因此构成 ...

山东科源制药股份有限公司 投资者关系管理制度 2025 年 9 月 山东科源制药股份有限公司 投资者关系管理制度 山东科源制药股份有限公司 投资者关系管理制度 第一章 总 则 第一条 为进一步推动山东科源制药股份有限公司（以下简称"公司"）完 善治理结构，规范公司投资者关系管理工作，根据《中华人民共和国公司法》、 《中华人民共和国证券法》等有关法律、法规、规章、中国证监会发布的《上市 公司与投资者关系工作指引》和深圳证券交易所（以下简称"证券交易所"）发 布的《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以 下简称"《自律监管指引》"）等有关业务规则的规定和《山东科源制药股份有 限公司章程》（以下简称"公司章程"），特制定本制度。 第二条 公司投资者关系管理是指公司通过信息披露与交流，加强与投资者 及潜在投资者之间的沟通，增进投资者对公司的了解和认同，提升公司治理水平， 以实现公司整体利益最大化和保护投资者合法权益。 第三条 公司投资者关系管理的目的是： （一）促进公司与投资者之间的良性关系，增进投资者对公司的进 ...